GLP-1 & Metabolic

A small-molecule NNMT inhibitor studied in early metabolic research; technically not a peptide, but commonly grouped with metabolic compounds in the community.

A synthetic fragment of human growth hormone (the 176-191 region) marketed for fat loss, but with disappointing human weight-loss evidence.

An investigational long-acting amylin analog studied for weight management, frequently in combination with semaglutide (the CagriSema combination).

An FDA-approved GLP-1 receptor agonist — the daily-injection predecessor to weekly agents like semaglutide — with established human trial data.

An investigational dual GLP-1 and glucagon receptor agonist studied for weight management and metabolic outcomes, with a notable trial program in China.

An investigational triple agonist targeting the GLP-1, GIP and glucagon receptors, notable for unusually large weight reduction in early human trials.

A GLP-1 receptor agonist with a strong human trial record and multiple FDA approvals for type 2 diabetes and chronic weight management.

An investigational dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic liver disease (MASH/NASH).

A small-molecule triple monoamine reuptake inhibitor (not a peptide) originally developed for neurological disease and later studied for obesity.

A dual GIP and GLP-1 receptor agonist with FDA approvals for type 2 diabetes and chronic weight management, supported by large randomized trials.